Charles Schwab Investment Management Inc Century Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 357,805 shares of IPSC stock, worth $268,353. This represents 0.0% of its overall portfolio holdings.
Number of Shares
357,805
Previous 355,331
0.7%
Holding current value
$268,353
Previous $607,000
40.53%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding IPSC
# of Institutions
66Shares Held
36.9MCall Options Held
8.7KPut Options Held
10.2K-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$4.06 Million1.66% of portfolio
-
Vr Adviser, LLC New York, NY5.39MShares$4.04 Million0.95% of portfolio
-
Boxer Capital, LLC San Diego, CA3.9MShares$2.93 Million0.35% of portfolio
-
Casdin Capital, LLC New York, NY3.21MShares$2.41 Million0.43% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$2.17 Million0.0% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $44.2M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...